India Cancer Diagnostics Market to Grow with a CAGR of 10.21% through 2030
Increase in the trend toward
personalized medicine and targeted therapies are expected to drive the India
Cancer Diagnostics Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Cancer
Diagnostics Market – India Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2030”, India Cancer Diagnostics Market was
valued at USD 4.56 billion in 2024 and is expected to reach USD 8.12 billion by
2030, growing with a CAGR of 10.21% in the forecast period. The awareness among
individuals regarding Cancer Diagnostics has created favorable conditions for
the India Cancer Diagnostics market. Multiple elements contribute to the
expanding demand for various Cancer Diagnostics products. The increasing cancer
burden in India stems from demographic shifts, lifestyle choices, environmental
factors, and awareness levels.
This rise in cancer cases not only challenges the
healthcare system but also drives growth in the Cancer Diagnostics market. As
India tackles this growing health concern, the diagnostics sector assumes a
vital role in early detection, precise diagnosis, and improving patient
outcomes. Collective efforts to boost cancer awareness and encourage early
detection have significantly influenced the market. Changing societal
perceptions, better access to screening, and innovation in diagnostic
technologies have positioned the market for significant growth. As more
individuals engage in preventive screenings, the demand for cancer diagnostics
is expected to rise, supporting improved outcomes and overall public health,
thereby accelerating market expansion.
Awareness initiatives have both educated the
population and enhanced access to screening services. The presence of mobile
units, diagnostic centers, and specialized facilities is increasing. This
ensures individuals can access screenings conveniently and affordably. In
today’s fast-paced environment, Cancer Diagnostics allows for early detection,
often before symptoms appear. Early diagnosis is crucial for improving
treatment success and full recovery. With limited time for medical
appointments, early detection supports more efficient and shorter treatment
courses, reducing hospital stays and aiding quicker recovery. Advanced
diagnostics like genetic profiling and biomarker analysis enable precision
medicine, allowing tailored treatment plans, reducing ineffective therapies,
and enhancing overall treatment efficiency.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "India Cancer Diagnostics Market”
Telemedicine platforms enabled patients to connect
with oncologists and diagnostic specialists remotely, eliminating the need for
physical appointments. In fast-paced urban regions of India, where traffic and
time constraints were significant issues, telemedicine improved access to
cancer diagnostic consultations. It minimized travel time and shortened
appointment wait periods. Advanced diagnostic tools, such as molecular testing
and imaging, offered quicker results than conventional methods. In today’s fast-moving
world, where timely decisions were crucial, these faster results facilitated
swift treatment planning. Both patients and doctors could act promptly without
unnecessary delays.
Cancer diagnostics also enhanced healthcare system
efficiency by ensuring timely and appropriate tests and treatments. In a
fast-paced medical landscape, these streamlined processes reduced delays,
optimized resources, and improved cancer care delivery. Technological progress
in point-of-care testing allowed rapid, accurate cancer diagnosis even at a
patient’s bedside or in smaller clinics. Portable diagnostic tools identified
biomarkers quickly, shortening the diagnostic window and supporting immediate
care decisions. In recent years, screening tools such as mammograms, Pap
smears, colonoscopies, and blood tests enabled early cancer or precancerous
condition detection. This early identification often occurred before symptoms
appeared, allowing for prompt treatment during the most curable stages and
potentially halting disease progression.
Genetic testing identified individuals at high risk
due to inherited mutations. With such insights, high-risk individuals took
preventive steps like frequent screenings, lifestyle changes, or preventive
surgeries. Advanced diagnostics, including imaging and pathology, ensured
accurate staging and assessment of cancer spread. Despite these advances,
limited healthcare infrastructure, high costs, low awareness, and stigma
remained major market hurdles.
The India Cancer Diagnostics Market is segmented into
product, type, application, test-type, end-user, regional distribution, and
company.
Based on test type, in 2024, the biopsy segment
emerged as the dominant player in India’s cancer diagnostics market, primarily
due to its critical role in confirming cancer diagnoses. A biopsy involves
extracting a small tissue sample from the body, which is then examined under a
microscope to detect the presence of cancer cells. It remains the gold standard
for cancer diagnosis, providing essential information about the type, grade,
and stage of cancer—key factors in determining the most effective treatment
plan. The rising incidence of cancer across India has significantly increased
the demand for biopsy procedures. As more individuals present with suspicious
symptoms, clinicians rely on biopsies to provide accurate and early diagnoses.
With a surge in public awareness about the importance of early cancer detection,
more patients are opting for prompt investigations, increasing the uptake of
biopsy services.
Government initiatives promoting early detection and
screening programs, coupled with private sector investment in diagnostic
technologies, have improved access to biopsy services across urban and
semi-urban areas. Advancements in biopsy techniques such as image-guided,
minimally invasive, and liquid biopsies have made the procedure safer, faster,
and more widely accepted. These factors collectively contributed to the biopsy
segment’s leading position in India’s cancer diagnostics landscape in 2024.
Based on end user, the hospital segment is projected to
experience rapid growth during the forecast period. Physicians, dieticians, and
other healthcare professionals are increasingly recommending Cancer Diagnostics
to their patients to enhance health and improve quality of life. Consequently,
prescription medicines are predominantly available in pharmacies, which is
expected to contribute to the growth of this segment. The
hypermarkets/supermarkets segment is anticipated to present favorable growth
opportunities in the forecast period due to its wide acceptance among
end-users. Factors such as organized product display panels, consumers'
willingness to pay premium prices for specific products, and the strong
relationship between sales executives and buyers facilitate a better
understanding of consumer preferences for products and brands. These factors
collectively contribute to the growth of this segment.
Based on region, the South India segment is poised to
be the fastest-growing market, offering lucrative growth opportunities for
Cancer Diagnostics players during the forecast period. Factors such as South
India, particularly states like Karnataka, Tamil Nadu, and Kerala, has made
substantial investments in healthcare infrastructure. The region is home to
some of India's premier healthcare institutions, including hospitals, research
centers, and cancer treatment facilities. The presence of well-established
healthcare infrastructure is a significant driver of market growth. South India
boasts renowned medical colleges, universities, and research institutions.
These institutions actively engage in cancer research, diagnostic innovation,
and medical education. The research environment fosters the development and
adoption of cutting-edge diagnostic technologies. The literacy rate in South
India is generally higher than the national average. This region has a more
educated and health-conscious population, which translates to increased
awareness about cancer and the importance of early detection.
Major companies operating in
India Cancer Diagnostics Market are:
·
Baxter Pharmaceuticals India Private
Limited.
·
Bristol-Myers Squibb India Private
Limited.
·
Cipla Ltd.
·
Roche Products (India) Private
Limited.
·
Glenmark Pharmaceuticals Ltd.
·
Lupin Ltd
·
Abbott India Laboratories Limited
·
BIO-RAD LABORATORIES (INDIA) PRIVATE
LIMITED.
·
Siemens Healthcare Private Limited.
·
Thermo Fisher Scientific India Private
Limited.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“Technological advancements and rising public awareness are
key drivers of the cancer diagnostics market. The shift toward personalized
medicine and targeted therapies has increased the demand for diagnostic tests
that detect specific biomarkers and genetic mutations. The growing interest in
preventive healthcare is boosting production and marketing of diagnostic
solutions. Manufacturers are adopting advanced technologies to improve
efficiency and meet rising demand. Consumer acceptance and ongoing innovation
continue to support market growth. As the focus on early detection and tailored
treatment increases, the cancer diagnostics market is expected to expand
steadily, offering improved outcomes and broader access to high-quality
diagnostic tools” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“India Cancer Diagnostics Market Segmented By Product
(Instruments, Consumables, Services), By Type (IVD, LDT, Imaging), By
Application (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer,
Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer,
Pancreatic Cancer, Ovarian Cancer, Others), By Test-Type (Biopsy, Others), By
End-User (Hospitals, Laboratories, Others), By Country, Competition, Forecast,
Opportunities, 2020-2030”, has evaluated the future growth
potential of India Cancer Diagnostics Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in India Cancer Diagnostics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com